Background The link between low-density lipoprotein cholesterol (LDL-C) levels and dementia risk is poorly understood, with conflicting evidence on the role of LDL-C and the impact of statin therapy ...

An investigational monoclonal antibody called bentracimab can safely and effectively reverse potentially catastrophic ...

Background: Dual antiplatelet therapy is the standard of care for acute coronary syndrome, but uncertainty exists regarding ...

"A patient on ticagrelor who needs emergency heart surgery is at high risk for developing serious bleeding during the surgery," he said. "If you delay the surgery, there's a risk the patient could ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

The second is for Brilinta, a treatment used to reduce the risk of heart attacks. Neither of these patent expirations should be a game changer for AstraZeneca. Soliris' sales in 2024 totaled $2.6 ...

Effient is often taken along with aspirin. Effient is available in tablet form to be taken by mouth. It comes in strengths of 5 mg and 10 mg. Ticagrelor, more commonly known by its brand name, ...

AstraZeneca's antiplatelet drug Brilinta has met its objectives in a 21,000-patient Phase III trial that could help the company meet its lofty ambitions for the drug. Updated results from the ...